Douglas Spriggs

5.1k total citations · 2 hit papers
10 papers, 1.9k citations indexed

About

Douglas Spriggs is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Douglas Spriggs has authored 10 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 6 papers in Cardiology and Cardiovascular Medicine and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Douglas Spriggs's work include Coronary Interventions and Diagnostics (6 papers), Cerebrovascular and Carotid Artery Diseases (4 papers) and Cardiac Imaging and Diagnostics (3 papers). Douglas Spriggs is often cited by papers focused on Coronary Interventions and Diagnostics (6 papers), Cerebrovascular and Carotid Artery Diseases (4 papers) and Cardiac Imaging and Diagnostics (3 papers). Douglas Spriggs collaborates with scholars based in United States, Slovakia and Belgium. Douglas Spriggs's co-authors include Stephen G. Ellis, Jeffrey J. Popma, Neal S. Kleiman, Dean J. Kereiakes, Eric J. Topol, Joel Greenberg, Gregg W. Stone, J. Tift Mann, Mary E. Russell and Patrick Hall and has published in prestigious journals such as JAMA, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Douglas Spriggs

10 papers receiving 1.8k citations

Hit Papers

Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockad... 2003 2026 2010 2018 2003 2005 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention
    2003 836 citations A. Michael Lincoff, John A. Bittl et al. JAMA profile →
  2. Comparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With Complex Coronary Artery Disease
    2005 612 citations Gregg W. Stone, Stephen G. Ellis et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas Spriggs United States 7 1.5k 1.3k 536 388 362 10 1.9k
Brent McLaurin United States 18 1.3k 0.9× 974 0.7× 345 0.6× 342 0.9× 258 0.7× 24 1.5k
GertJan Laarman Netherlands 23 1.5k 1.0× 1.6k 1.2× 329 0.6× 691 1.8× 612 1.7× 51 2.1k
Russell Raymond United States 22 897 0.6× 798 0.6× 168 0.3× 409 1.1× 384 1.1× 49 1.3k
Andrew Berke United States 11 1.3k 0.9× 763 0.6× 430 0.8× 289 0.7× 282 0.8× 16 1.6k
Michael Attubato United States 17 1.4k 0.9× 1.2k 0.9× 178 0.3× 658 1.7× 399 1.1× 49 1.8k
Ferdinand Leya United States 16 1.2k 0.8× 1.0k 0.8× 137 0.3× 568 1.5× 221 0.6× 49 1.6k
Frédérique Bigonzi United States 12 1.8k 1.2× 741 0.6× 970 1.8× 413 1.1× 78 0.2× 20 2.0k
Thomas Zanchin Switzerland 22 1.7k 1.1× 1.2k 0.9× 236 0.4× 485 1.3× 357 1.0× 51 2.1k
Thomas M. Broderick United States 21 1.1k 0.7× 799 0.6× 255 0.5× 396 1.0× 131 0.4× 40 1.4k
Thomas Shimshak United States 23 1.2k 0.8× 1.1k 0.9× 159 0.3× 557 1.4× 244 0.7× 54 1.5k

Countries citing papers authored by Douglas Spriggs

Since Specialization
Citations

This map shows the geographic impact of Douglas Spriggs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Spriggs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Spriggs more than expected).

Fields of papers citing papers by Douglas Spriggs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Spriggs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Spriggs. The network helps show where Douglas Spriggs may publish in the future.

Co-authorship network of co-authors of Douglas Spriggs

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Spriggs. A scholar is included among the top collaborators of Douglas Spriggs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Spriggs. Douglas Spriggs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Price, Matthew J., Ajay J. Kirtane, Stanley Chetcuti, et al.. (2023). Three-Year Outcomes After Bifurcation Stenting With Zotarolimus-Eluting Stents: Final Results From the RESOLUTE ONYX Postapproval Study. Journal of the Society for Cardiovascular Angiography & Interventions. 2(6). 101116–101116. 1 indexed citations
2.
Price, Matthew J., Ajay J. Kirtane, Stanley Chetcuti, et al.. (2022). B-25 | Two-Year Outcomes in Patients with Bifurcation Lesions treated with Resolute ONYX ZES: Final Results from the RESOLUTE ONYX Bifurcation Study. Journal of the Society for Cardiovascular Angiography & Interventions. 1(3). 100132–100132. 2 indexed citations
3.
Kirtane, Ajay J., Stanley Chetcuti, Petra Poliačiková, et al.. (2021). ONE YEAR CLINICAL OUTCOMES IN PATIENTS WITH CORONARY BIFURCATION LESIONS: RESULTS FROM THE RESOLUTE ONYX BIFURCATION STUDY. Journal of the American College of Cardiology. 77(18). 965–965. 1 indexed citations
4.
Price, Matthew J., Shigeru Saito, Richard Shlofmitz, et al.. (2017). First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter. JACC: Cardiovascular Interventions. 10(14). 1381–1388. 39 indexed citations
5.
Price, Matthew J., Richard Shlofmitz, Douglas Spriggs, et al.. (2017). Safety and efficacy of the next generation Resolute Onyx zotarolimus‐eluting stent: Primary outcome of the RESOLUTE ONYX core trial. Catheterization and Cardiovascular Interventions. 92(2). 253–259. 28 indexed citations
6.
Yeung, Alan C., Martin B. Leon, Ash Jain, et al.. (2011). Clinical Evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries. Journal of the American College of Cardiology. 57(17). 1778–1783. 102 indexed citations
7.
Stone, Gregg W., Stephen G. Ellis, Louis Cannon, et al.. (2005). Comparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With Complex Coronary Artery Disease. JAMA. 294(10). 1215–1215. 612 indexed citations breakdown →
8.
Lincoff, A. Michael, Neal S. Kleiman, Dean J. Kereiakes, et al.. (2004). Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization. 13 indexed citations
9.
Lincoff, A. Michael, John A. Bittl, Robert A. Harrington, et al.. (2003). Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention. JAMA. 289(7). 853–853. 836 indexed citations breakdown →
10.
Ohman, E. Magnus, Neal S. Kleiman, Gerald M. Gacioch, et al.. (1997). Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa Integrin Receptor Blockade With Integrilin in Acute Myocardial Infarction. Circulation. 95(4). 846–854. 282 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brent McLaurin Breakdown of academic impact, for papers by GertJan Laarman Breakdown of academic impact, for papers by Russell Raymond Breakdown of academic impact, for papers by Andrew Berke Breakdown of academic impact, for papers by Michael Attubato Breakdown of academic impact, for papers by Ferdinand Leya Breakdown of academic impact, for papers by Frédérique Bigonzi Breakdown of academic impact, for papers by Thomas Zanchin Breakdown of academic impact, for papers by Thomas M. Broderick Breakdown of academic impact, for papers by Thomas Shimshak
Rankless by CCL
2026